Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies.

ABSTRACT:

Purpose

The receptor tyrosine kinase rearranged during transfection (RET) can be oncogenically activated by gene fusions or point mutations. Multikinase inhibitors such as cabozantinib, lenvatinib and vandetanib have demonstrated activity in RET-dependent malignancies, and selective RET inhibitors (Selpercatinib and Pralsetinib) are in clinical trials. However, the responsiveness of RET-dependent malignancies to immune checkpoint inhibitors (ICIs) is unknown. We compared the time to treatment discontinuation (TTD) for ICI versus non-ICI therapy in patients with malignancies harbouring activating RET mutations or fusions (RET+).

Methods

A retrospective review of all RET+ patients who were referred to the phase I clinical trials programme at the University of Texas MD Anderson

SUBMITTER: Hegde A 

PROVIDER: S-EPMC7590373 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature